Comparative efficacy and cost–utility of combined cataract and minimally invasive glaucoma surgery in primary open-angle glaucoma

• Published in: International ophthalmology 2020-06, Vol.40 (6), p.1469-1479
• Main Authors: Bartelt-Hofer, Jose, Flessa, Steffen
• Format: Article
• Language: English
• Subjects: Cataract - complications; Cataract - economics; Cataract Extraction - methods; Clinical trials; Cost-Benefit Analysis; Eye surgery; Glaucoma; Glaucoma, Open-Angle - complications; Glaucoma, Open-Angle - economics; Glaucoma, Open-Angle - surgery; Health services; Humans; Implants; Intraocular pressure; Measurement methods; Medicine; Medicine & Public Health; Minimally Invasive Surgical Procedures - economics; Minimally Invasive Surgical Procedures - methods; Ophthalmology; Original Paper; Patient Acceptance of Health Care; Patients; Stents; Surgery; Trabeculectomy - economics; Trabeculectomy - methods; Visual Acuity
• ISSN: 0165-5701; 1573-2630
• DOI: 10.1007/s10792-020-01314-7

Purpose To assess the comparative efficacy and the long-term cost–utility of alternative minimally invasive glaucoma surgeries (MIGSs) when combined with cataract surgery in patients with primary open-angle glaucoma (POAG). Methods Treatment effects, as measured by the 1-year reduction in intraocular pressure (IOP), were estimated with an adjusted indirect treatment comparison. Evidence from randomized clinical trials was identified for four different MIGS methods. A disease-transition model was developed by capturing clinically relevant POAG stages and the expected natural disease evolution. Outcomes of the disease-transition model were the comparative utility [quality-adjusted life years (QALYs)], cost and cost–utility of included strategies in a lifetime horizon. Results Estimated 1-year IOP reductions were: cataract surgery − 2.05 mmHg (95% CI − 3.38; − 0.72), one trabecular micro-bypass stent − 3.15 mmHg (95% CI − 5.66; − 0.64), two trabecular micro-bypass stents − 4.85 mmHg (95% CI − 7.71; − 1.99) and intracanalicular scaffold − 2.25 mmHg (95% CI − 4.87; 0.37). Discounted outcomes from the disease-transition model appraised the strategy of two trabecular micro-bypass stents with cataract surgery in the moderate POAG stage as the one providing the greatest added value, with 10,955€ per additional QALY. Improved outcomes were seen when assessing MIGS in the moderate POAG stage. Conclusions When indirectly comparing alternative MIGS methods combined with cataract surgery, the option of two trabecular micro-bypass stents showed both a superior efficacy and long-term cost–utility from a German perspective. Moreover, outcomes of the disease-transition model suggest POAG patients to beneficiate the most from an earlier intervention in the moderate stage contrary to waiting until an advanced disease is present.